BORAYER Secures Tens of Millions in Series B Funding from Yuansheng Ventures to Advance Innovative Wound Repair Biomaterials

Recently, Jiangxi BORAYER Biotechnology Co., Ltd. (“BORAYER”) completed a Series B financing round worth tens of millions of RMB, with exclusive investment from YuanBio Venture Capital. WinX Capital served as the exclusive financial advisor for this round.

Established in 2017, BORAYER is committed to making tissue regeneration a reality. Specializing in the research, development, and production of biomaterials for wound repair, the company provides clinical medicine with a series of high-end consumables for rapid hemostasis, wound repair, and guided tissue regeneration, featuring industry-leading technological standards.

Since the beginning of the 21st century, China’s medical biomaterials industry has transitioned from its nascent stage to a phase of rapid growth. According to statistics, annual sales of biomedical materials in China have exceeded RMB 100 billion. Conservatively estimated, China is poised to become the world’s second-largest market for biomedical materials within the next decade. Globally, the biomedical materials industry in developed countries and regions such as Europe and the United States started earlier, driven primarily by demand for product upgrades and replacements. These markets impose relatively higher requirements on technological sophistication and product quality, featuring large market sizes and stable growth. In contrast, emerging markets represented by China exhibit both demand for product adoption and for upgrades, resulting in a faster overall market growth rate. However, China’s biomedical materials industry suffers from a weak foundational base, with high-end products still predominantly reliant on imports. In the niche segment of wound repair, the market is dominated by multinational giants such as Johnson & Johnson, B. Braun, and Stryker.

BORAYER’s founding team, anchored by master’s and doctoral graduates from Tsinghua University, spans multiple disciplines including biomaterials, chemistry, and clinical medicine, with a focus on developing wound repair products that are “exclusive in China and world-class internationally.” The company has established multiple polymer biomaterial technology platforms, covering starch and its derivatives, biological polysaccharides, protein-based compounds, polyurethane compounds, and polyethylene glycol (PEG) and its derivatives. Building on these technological platforms, BORAYER has continuously advanced R&D to form a comprehensive portfolio of wound repair products and next-generation biological hemostatic materials. Additionally, the company maintains a pipeline of more than ten reserve products, most of which are high-value surgical consumables with individual market sizes exceeding RMB 2 billion. Several of these products have completed animal studies and entered the registration application stages with China’s National Medical Products Administration (NMPA), the European Union’s CE marking, and the U.S. Food and Drug Administration (FDA).

The founder and CEO of BORAYER stated that next-generation biomedical materials require support from multiple foundational platform technologies, rather than a superficial combination of simple techniques. The company’s R&D team has accumulated extensive experience in molecular-level modification and functionalization of materials, enabling its products to better address clinical pain points. To date, the company has obtained seven medical device registration certificates and is actively advancing pre-market preparations for other products. This financing will significantly propel the clinical research and regulatory submission processes for its core products, while accelerating the expansion of its sales channels.

Yin Jie, Partner at YuanBio Venture Capital, stated: “BORAYER has established multiple biomaterials technology platforms and a comprehensive R&D system, creating substantial technical barriers to entry. The company is capable of initiating the development and market launch of five to ten Class III medical device products annually. In the field of biomaterials, Chinese companies represented by BORAYER are at the forefront of global innovation. We are confident in this team with strong technical expertise from Tsinghua University and look forward to continuing our support in helping BORAYER become a great medical innovation enterprise.”

BORAYER, founded by a team from Tsinghua University, is on a mission to make tissue regeneration a reality. Specializing in the research, development, and production of biomedical materials, it strives to become a leader in the field of biomedical materials.

The company has established multiple leading polymer biomaterial technology platforms, including those based on starch and its derivatives, biological polysaccharides, protein extracts, polyurethane compounds, and PEG and its derivatives. These platforms support the provision of a series of high-end medical consumables for clinical applications, such as rapid hemostasis, wound repair, and guided tissue regeneration, with product technologies ranking among the industry leaders.

The company is equipped with a 5,000-square-meter biomaterials laboratory, a polymer laboratory, cell culture rooms, an animal laboratory, and a Class 10,000 clean workshop. Meanwhile, it has established strategic partnerships with universities such as Tsinghua University and Huazhong University of Science and Technology, and built close academic ties with renowned Grade IIIA clinical institutions including China-Japan Friendship Hospital, Peking University Third Hospital, and Beijing Tsinghua Changgung Hospital, thereby constructing a comprehensive R&D ecosystem.

The company has established a complete industrialization system for biomaterials and is a platform-based innovative enterprise with capabilities in product R&D, manufacturing, registration, and sales. It has filed over 30 patent applications, received more than 20 patent grants, undertaken over 10 national and local scientific research projects, and obtained seven medical device registration certificates. The company boasts the most comprehensive wound repair product portfolio in China, including surgical hemostatic materials, surgical adhesives, biological glues, and wound care consumables. Additionally, it has a pipeline of more than 10 reserve products, mostly exclusive domestic offerings of international premier quality, with individual product market sizes exceeding RMB 2 billion. Several of these products have entered the registration application stages with China’s NMPA, the EU CE, and the US FDA.

YuanBio Venture Capital is an investment firm focused on the healthcare sector in its early and growth stages. Based in Suzhou BioBAY, it has a global reach. Currently managing approximately RMB 5 billion in assets, YuanBio has completed investments in over 60 high-quality projects, primarily involving new drug development, medical devices, in vitro diagnostics, and healthcare services. It has achieved substantial investment returns and has been repeatedly recognized as one of the Top 10 venture capital funds in China’s healthcare sector and as one of the most active healthcare investment institutions in China. YuanBio brings together a team of seasoned professional investors and a global advisory board of leading scientific experts, possessing extensive experience in entrepreneurship, venture capital, and corporate operations within the biopharmaceutical industry and related fields. Leveraging its focused strategy and abundant industry resources, YuanBio is committed to becoming one of the most successful healthcare venture capital funds in China.

WinX Capital is a leading investment bank in China’s healthcare sector. Five members of its founding team hold Ph.D. degrees in Global Finance from the PBC School of Finance at Tsinghua University, while its frontline professionals boast an average of over 10 years of experience in management, investment, and M&A, with cumulative transaction values nearing RMB 30 billion. Headquartered in Beijing and Shanghai, with offices in Shenzhen and Suzhou, WinX Capital serves more than 3,000 active institutional investors and industrial conglomerates.